The Top Institute Pharma (TI Pharma) of the Netherlands has decided to allocate €16 million over four years to co-develop with Sanaria Inc a malaria vaccine which is based on the concept of inducing immunity in humans through the use of a whole, attenuated malaria parasite.
A four-year project aimed at identifying target molecules for the development of new treatments for Alzheimer’s and Parkinson’s diseases is being launched in the Netherlands,
Children who are diagnosed with cancer have the same prospect for survival as a parent who was also diagnosed with the same cancer.
Imperial Innovations Group Plc, which started operations as a university technology transfer office in 1986, has transformed itself into a venture capital company with about half of its investments in life science companies.
Modern Biosciences Plc has signed an exclusive worldwide licensing agreement with the University of Aberdeen to develop a series of small molecule compounds for the treatment of rheumatoid arthritis (RA).
A new UK public-private partnership called Stem Cells for Safer Medicines is asking research-oriented firms to join it in an investigation of whether stem cells can be used to determine the safety of medicines under development.
The Dutch government has decided to allocate €271 million for the second phase of a national programme that integrates genomics into several branches of science, including the development of new medicines. The programme is known as the Netherlands Genomics Initiative (NGI).
The European Investment Bank (EIB), the long-term financing arm of the European Union, has begun rolling out a new borrowing facility for research-intensive companies which might otherwise be unable to obtain capital.
The Bioprocessing Research Industry Club (BRIC) has awarded £3.5 million to researchers at seven UK universities for projects that will make the manufacture of biopharmaceuticals more efficient.
Stem Cell Sciences Plc said it is coordinator of a new collaboration that will design bioassays that can be used to discover new candidates for treating cancer, Alzheimer’s disease, stroke and epilepsy.